A Takeda spinout builds case for its Parkinson’s drug

Phase 3solengeprasPositive

AI Analysis

Summary

Cerevance, a Takeda spinout, has completed Phase 3 trials for solengepras, a novel Parkinson's disease treatment, and plans to meet with the FDA to determine regulatory next steps.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Phase 3 data completed; company plans FDA meeting to determine next steps

Importance:6/10

Sentiment:

0.50

Parkinson's diseasesolengeprasCerevanceTakeda spinoutFDA meeting

Related Companies

$TAK

Read the original article

Published by BioPharma Dive on October 7, 2026 12:01 PM

Read Original